Pulse Biosciences, Inc. PLSE Cash Flow

Pulse biosciences, inc. (PLSE)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Cash flows from operating activities:
Net loss
-48,765	-46,971	-42,136	-41,151	-38,955	-37,545	-37,295	-34,020	-31,037	-25,567	-19,673	-14,954	-11,032	-9,518	-7,726	-5,710	-4,051	-2,811	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
436	494	561	636	654	645	614	596	465	336	220	97	96	94	90	77	63	51	0	0	0
Amortization of intangible assets
665	666	666	665	666	665	665	665	665	665	665	666	665	665	666	666	666	666	0	0	0
Stock-based compensation
11,552	11,287	10,089	10,803	11,279	12,338	14,511	14,468	14,083	10,926	6,646	3,534	940	870	762	630	541	402	0	0	0
Net premium amortization and discount on available-for-sale securities
429	521	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net premium amortization and discount on available-for-sale securities
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net discount amortization on investments
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Change in deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,657	0	0	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-5	226	342	747	182	367	583	444	115	144	409	358	397	415	243	493	-4	12	0	0	0
Right-of-use assets
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term assets
354	393	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Accounts payable
-31	646	535	75	256	490	367	651	162	517	468	518	486	3	152	78	103	125	0	0	0
Accrued expenses
318	841	397	539	673	387	661	308	348	245	397	454	-1	246	267	71	203	305	0	0	0
Lease liabilities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current and non-current liabilities
-	-	2,137	2,076	-294	-397	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-39	0	0	0
Net cash used in operating activities
-36,477	-34,185	-31,297	-30,182	-26,208	-23,896	-21,551	-18,118	-13,606	-11,087	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-4,322	-	0	0	0
Cash flows from investing activities:
Purchases of property and equipment
734	608	678	217	287	276	0	0	0	-	-	-	-	64	0	0	0	-	-	-	-
Purchases of investments
36,813	77,993	73,479	66,255	65,326	40,297	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of investments
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Maturities of investments
73,500	68,500	63,750	55,500	44,000	41,815	42,179	29,214	23,663	23,148	0	0	0	-	-	-	-	-	-	-	-
Sales of investments
-	-	-	-	-	24,875	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used) in investing activities
35,953	-10,101	-10,407	-10,972	-21,613	26,117	-5,364	-7,511	-9,189	-22,998	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used) in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock under employee stock purchase plan
0	-	-	-	0	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercises of stock options
0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-148	82	44,943	45,140	45,690	45,496	823	30,433	30,711	35,382	0	0	0	-	-	-	-	-	-	-	-
Net increase (decrease) in cash
-672	-44,204	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	7,916	-	27,795	-18,224	646	-1,517	-321	14,278	-4,447	-3,403	0	0	0
Supplemental disclosure of noncash investing and financing activities:
Change in unrealized gains on available-for-sale securities
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-